DNA免疫治疗后 - 免疫和抗病毒反应

StephenW

nature.com > Journal home > Table of Contents
Original Article

Molecular Therapy (5 December 2013) | doi:10.1038/mt.2013.274
   
Immunological and Antiviral Responses After Therapeutic DNA Immunization in Chronic Hepatitis B Patients Efficiently Treated by Analogues

O Godon, H Fontaine, S Kahi, JF Meritet, D Scott-Algara, S Pol, ML Michel, M Bourgine and ; for the ANRS HB02 study group
Abstract

A substudy of a phase I/II, prospective, multicenter clinical trial was carried out to investigate the potential benefit of therapeutic vaccination on hepatitis B e antigen-negative patients with chronic hepatitis B (CHB), treated efficiently with analogues. Patients were randomized in 2 arms, one receiving a hepatitis B virus (HBV) envelope DNA vaccine, and one without vaccination. At baseline, HBV-specific interferon (IFN)-γ–producing T cells were detected in both groups after in vitro expansion of peripheral blood mononuclear cells. Vaccine-specific responses remained stable in the vaccine group, whereas in the control group the percentage of patients with HBV-specific IFN-γ–producing T cells decreased over time. The vaccine-specific cytokine-producing T cells were mostly polyfunctional CD4+ T cells, and the proportion of triple cytokine-producer T cells was boosted after DNA injections. However, these T-cell responses did not impact on HBV reactivation after stopping analogue treatment. Importantly, before cessation of treatment serum hepatitis B surface antigen (HBsAg) titers were significantly associated with DNA or HBsAg clearance. Therapeutic vaccination in CHB patients with persistent suppression of HBV replication led to the persistence of T-cell responses, but further improvements should be searched for to control infection after treatment discontinuation.

StephenW

免疫和抗病毒反应治疗后DNA免疫在慢性乙型肝炎患者由类似物有效地进行处理

Ø Godon ，H方丹，S KAHI ， JF Meritet ，D斯科特 - Algara ，S波尔， ML米歇尔，M Bourgine和;为ANRS HB02研究组
摘要

一个I / II期的亚组研究，前瞻性，多中心临床试验进行了探讨治疗性疫苗对B型肝炎e抗原阴性慢性乙型肝炎（CHB ） ，有效地与类似物治疗的潜在益处。患者被随机分配在2臂，一个接收一个乙肝病毒（HBV）包膜的DNA疫苗，和一个没有接种。在基线时， HBV特异性干扰素（IFN） - γ的T细胞进行了体外扩增外周血单核细胞后，两组检测。疫苗特异性反应，疫苗组中保持稳定，而对照组患者的HBV特异性的IFN - γ的T细胞的百分率随时间降低。该疫苗特异性细胞因子的T细胞大多多官能CD4 + T细胞，和三细胞因子生产的T细胞的比例的DNA注射后升压。然而，这些T细胞的反应并没有对HBV再激活停止类似物治疗后的影响。重要的是，停止治疗血清乙肝表面抗原前（ HBsAg）的滴度显著与DNA或HBsAg清除有关。治疗性疫苗在慢性乙型肝炎患者的HBV复制持续抑制导致T细胞反应的持久性，但进一步的改进应搜索进行治疗停药后控制感染。

疯一点好

有较好效果的治疗性疫苗？希望早日试验成功，

StephenW

回复 疯一点好 的帖子

有较好效果的治疗性疫苗？没有, 古巴的Nasvac?

我个人的看法：
1. 这些疫苗都能够提高T细胞的生产; 但对控制/清除感染的肝细胞的影响很小.
2.我们缺少某些配料，或时机不对?

咬牙硬挺

感谢分享

17017196

我等呀等！！！！头发开始白了